Pharming Group (PHAR)

Executive Summary

Pharming Group is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product, Ruconest (recombinant human C1 esterase inhibitor), is approved for hereditary angioedema (HAE) and provides a steady revenue stream. The company's primary pipeline asset is leniolisib, an oral PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency with no approved therapies. Leniolisib has shown promising efficacy and safety in Phase 2/3 trials, and Pharming has submitted regulatory filings in the US and EU. With a strong balance sheet and commercial infrastructure in place, Pharming is poised for significant growth pending leniolisib's approval. The company is also exploring leniolisib in other PI3Kδ-related disorders, expanding its potential market. Overall, Pharming represents a compelling opportunity as it transitions from a single-product company to a multi-product rare disease player.

Upcoming Catalysts (preview)

• Q3 2026FDA Decision on Leniolisib for APDS85% success
• Q4 2026EU CHMP Opinion on Leniolisib for APDS80% success
• Q4 2026Phase 3 APDS Trial Data Readout (NCT05693129)90% success